Payment overview · 2025
General Payments
$373.67
6 reported records · 4 companies
Healthcare provider profile · identity verified
David D Oh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · TORRANCE, CA · NPI 1366549255
Verified facts
What the public records show
CMS Open Payments records show David D Oh, M.D. received $373.67 in general payments during 2025 across 6 reported records.
Stryker Corporation accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $158.40 | 42.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $124.99 | 33.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.44 | 18.6% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.84 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.67 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NICO BRAINPATH Normalized: nico brainpath |
Device | Stryker Corporation | $158.40 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.44 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.44 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1438 | 375 |
| Amlodipine Besylate | Amlodipine Besylate | 1088 | 277 |
| Losartan Potassium | Losartan Potassium | 671 | 169 |
| Metformin Hcl | Metformin Hcl | 457 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 87 |
| Januvia | Sitagliptin Phosphate | 349 | 54 |
| Simvastatin | Simvastatin | 342 | 94 |
| Omeprazole | Omeprazole | 325 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 81 |
| Donepezil Hcl | Donepezil Hcl | 259 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 71 |
| Gabapentin | Gabapentin | 254 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 240 | 56 |
| Jardiance | Empagliflozin | 195 | 30 |
| Vascepa | Icosapent Ethyl | 182 | 35 |
| Creon | Lipase/Protease/Amylase | 177 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 46 |
| Finasteride | Finasteride | 171 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 152 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 41 |
| Atenolol | Atenolol | 139 | 35 |
| Naproxen | Naproxen | 137 | 70 |
| Alendronate Sodium | Alendronate Sodium | 124 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 21 |
| Famotidine | Famotidine | 102 | 28 |
| Trazodone Hcl | Trazodone Hcl | 101 | 28 |
| Meloxicam | Meloxicam | 95 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 19 |
| Montelukast Sodium | Montelukast Sodium | 92 | 35 |
| Allopurinol | Allopurinol | 91 | 24 |
| Benazepril Hcl | Benazepril Hcl | 87 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 87 | 24 |
| Eliquis | Apixaban | 86 | 13 |
| Azithromycin | Azithromycin | 83 | 74 |
| Furosemide | Furosemide | 83 | 30 |
| Metformin Hcl Er | Metformin Hcl | 82 | 22 |
| Zenpep | Lipase/Protease/Amylase | 80 | 20 |
| Memantine Hcl | Memantine Hcl | 78 | 15 |
| Ezetimibe | Ezetimibe | 76 | 26 |
| Ibuprofen | Ibuprofen | 73 | 22 |
| Lorazepam | Lorazepam | 69 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 20 |
| Linzess | Linaclotide | 67 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 18 |
| Carvedilol | Carvedilol | 64 | 14 |
| Lisinopril | Lisinopril | 63 | 18 |
| Valsartan | Valsartan | 63 | 16 |
| Potassium Chloride | Potassium Chloride | 62 | 19 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 55 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 12 |
| Celecoxib | Celecoxib | 51 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 17 |
| Prednisone | Prednisone | 49 | 33 |
| Nateglinide | Nateglinide | 48 | 12 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 31 |
| Methotrexate | Methotrexate Sodium | 42 | 11 |
| Levofloxacin | Levofloxacin | 41 | 36 |
| Nifedipine Er | Nifedipine | 41 | 11 |
| Glycopyrrolate | Glycopyrrolate | 40 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Enulose | Lactulose | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Rybelsus | Semaglutide | 38 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Mirtazapine | Mirtazapine | 30 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Acyclovir | Acyclovir | 29 | 23 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Dutasteride | Dutasteride | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | 17 |
| Lumigan | Bimatoprost | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 21 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Enbrel Sureclick | Etanercept | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | 11 |
| Minoxidil | Minoxidil | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Mupirocin | Mupirocin | 16 | 12 |
| Digoxin | Digoxin | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 14 | 14 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.67 · 6 records | Stryker Corporation | CAPVAXIVE, EYLEA HD, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, NICO BRAINPATH | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error